Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.35 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18867127 | 0.84 | ZDHHC20 (0.36) | ALDH1A1DPP4ZDHHC20ZDHHC2 | |
| SCHEMBL18431760 | 0.84 | ZDHHC20 (0.36) | ALDH1A1DPP4ZDHHC20ZDHHC2 | |
| SCHEMBL9004572 | 0.83 | ZDHHC20 (0.39) | ALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL21166401 | 0.83 | ZDHHC20 (0.38) | ALDH1A1DPP4ZDHHC20ZDHHC2SMN1; SMN2 | |
| SCHEMBL16419896 | 0.81 | ZDHHC20 (0.41) | ALDH1A1ZDHHC20ZDHHC2 | |
| SCHEMBL23604912 | 0.81 | — | — | |
| SCHEMBL22753401 | 0.81 | — | — | |
| SCHEMBL22753396 | 0.81 | — | — | |
| SCHEMBL3478503 | 0.81 | ALDH1A1 (0.41) | ALDH1A1DPP4ZDHHC20ZDHHC2SMN1; SMN2 | |
| SCHEMBL19800938 | 0.80 | ZDHHC20 (0.42) | ALDH1A1DPP4ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718630-B2 | Compositions and methods for treating cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2023-05-11 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-04 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | AVILA THERAPEUTICS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029610-A1 | Heteroaryl Compounds and Uses Thereof | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885DPP4 125/4885ZDHHC20 958/4885 |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | ALDH1A1 1767/4885DPP4 3273/4885ZDHHC20 1684/4885 |
| US-20230135350-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885DPP4 4590/4885ZDHHC20 1528/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | ALDH1A1 1767/4885DPP4 3273/4885ZDHHC20 1684/4885 |
| US-20230148061-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | ALDH1A1 1195/4885DPP4 341/4885ZDHHC20 1457/4885 |
| US-20080300268-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | ALDH1A1 261/4885DPP4 138/4885ZDHHC20 1003/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885DPP4 125/4885ZDHHC20 958/4885 |
| US-11718630-B2 | Compositions and methods for treating cancer | KRAS, HRAS, NRAS | ALDH1A1 2792/4885DPP4 4590/4885ZDHHC20 1528/4885 |
| US-20090176858-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885DPP4 8/4885ZDHHC20 690/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885DPP4 125/4885ZDHHC20 958/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | ALDH1A1 684/4885DPP4 125/4885ZDHHC20 958/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | ALDH1A1 2792/4885DPP4 4590/4885ZDHHC20 1528/4885 |
| US-20090306085-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885DPP4 8/4885ZDHHC20 690/4885 |
| US-20100041674-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885DPP4 8/4885ZDHHC20 690/4885 |
| US-20100041591-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | PEPD, CTRL, CTSC | ALDH1A1 1344/4885DPP4 8/4885ZDHHC20 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.